Company intelligence / Profile preview
DermaGen
Lund, Swedendermagen.se ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DermaGen reported successful Phase I/IIa clinical trial for Atopic Dermatitis. Their lead candidate DPK-060 is a novel antimicrobial treatment that has shown promising results.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Antimicrobial peptides
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Karolinska DevelopmentPergamum AB
Beyond the preview
Go deeper on DermaGen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DermaGen.